Introduction {#s1}
============

The therapeutic options for the management of metastatic melanoma in BRAF-mutated patients have improved dramatically with the development of targeted and immune checkpoint based therapies. The BRAF activating mutation is present in 40--50% of melanomas, providing an important therapeutic target that can be clinically exploited by inhibiting the MAPK/ERK signaling pathway ([@B1]). The combination of BRAF and MEK inhibition is associated with improved overall survival (OS) and may reduce the incidence of resistance ([@B2], [@B3]). Indeed, Schadendorf et al. reported that pooled analyses of clinical trials of dabrafenib and trametinib revealed a 3 year overall survival (OS) rate of 44% ([@B4]). Recently updated data revealed a 5 year OS of 34% ([@B5]). In patients with favorable prognostic factors, including a normal serum lactate dehydrogenase (LDH) level, the sum of lesion diameters \<66 mm and metastases in \<3 organs, the 3 year progression free survival (PFS) rate was 42% ([@B4]). Similarly, Hauschild et al. reported 3 year OS rates of 53.3 % in patients with favorable prognostic features treated with cobimetinib and vemurafenib in a retrospective analysis of data from 4 randomized clinical trials ([@B6]). In fact, targeted therapy leads to a favorable tumor microenvironment in melanoma, with increased CD8 positive T cell infiltration and PD-L1 expression, suggesting a potential synergistic effect with immunotherapy ([@B7]).

Pending the results of ongoing clinical trials, the optimal first-line treatment strategy remains unclear and is likely to remain patient- and tumor-specific. Given the rapid response to targeted therapy, accompanied by a dramatic decrease in overall tumor load, the decision to commence targeted therapy in patients with BRAF V600 mutations may be favored in the context of symptomatic disease and the presence of adverse prognostic markers, including raised serum LDH concentrations, ECOG performance status\> 1, younger patients, and those with brain and/or metastases at multiple sites ([@B8], [@B9]). Typically, resistance to targeted therapy occurs after a median treatment time of 13 months. The use of immune checkpoint based therapies presents an important treatment option in the context of resistance to targeted therapies; the use of anti-programmed death protein (PD)-1 therapies is associated with an impressive overall response and level of disease control, albeit with a slower onset of action, but potentially a more durable effect ([@B10], [@B11]). Furthermore, the published data points toward a more favorable outcome in patients with brain metastases treated with combined immune checkpoint therapy with nivolumab and ipilimumab ([@B12]). At present, the decision as to whether to first employ targeted- or immune checkpoint therapy in patients with BRAF positive melanoma is reached after careful consideration of the overall disease burden, LDH levels, the presence of central nervous system metastases and clinician/individual patient preference. Several trials are currently examining the efficacy of sequenced targeted and immunotherapy (NCT02902029, NCT03235245) in order to establish whether sequential treatment represents a useful treatment strategy to deliver and sustain disease control.

Pending the results from these trials, we describe our clinical experience in 11 patients with melanoma stage IV, who were initially treated with targeted therapy and switched to immune checkpoint therapy (i) electively (based on partial or complete response and to prevent resistance) or (ii) in response to disease progression, in a sequential order.

Patients and Methods {#s2}
====================

We retrospectively analyzed the clinical course of 11 patients with BRAF V600 mutation positive malignant melanoma who commenced targeted therapy between 11/2012 and 12/2017 in our center ([Figure 1](#F1){ref-type="fig"}). A partial or complete radiological response was required in order to justify electively switching treatment from targeted to immune therapy to prevent the development of resistance. When staging examinations (CT/MRI) revealed disease progression the treatment was switched from targeted to immune therapy in a reactive manner due to an inadequate treatment response. The retrospective analysis was approved by the University of Luebeck\'s ethics committee (19-117A). Graph Pad Prism (Version 8.0.2) was used for the survival analyses and survival curves were compared with log rank (Mantel-Cox) tests. A *p* \< 0.05 was considered significant.

![Overall survival in the elective and reactive cohorts. Whilst there was no significant difference in overall survival between the cohorts **(A)**, exclusion of the outlier patient, the only patient to have received chemotherapy prior to the switch from targeted to immunotherapy, and the patient who committed suicide, revealed a significant (*p* = 0.01) difference in overall survival **(B)**.](fmed-06-00257-g0001){#F1}

Results {#s3}
=======

Elective Switching From Targeted to Immunotherapy Is Associated With Improved Overall Survival
----------------------------------------------------------------------------------------------

In order to ascertain the clinical course and calculate the overall survival of patients who were treated with sequential targeted therapy followed by immunotherapy a retrospective analysis of the electronic case notes was performed. Patients were retrospectively assigned to an "elective" or "reactive" cohort depending on whether therapy was switched electively on the basis of a radiological partial or complete response or reactively due to disease radiographic disease progression and/or intolerable side-effects (see [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}). There were no significant differences between the baseline characteristics of the groups in terms of age, baseline lactate dehydrogenase, and serum S100 concentrations.

###### 

Patient characteristics in both the elective and reactive cohorts.

  ------------------------------------------------------------------------------------------
  **Patient**\                               **Elective**\   **Reactive**\   ***p* value**
  **characteristics**                        **group**       **group**       
  ------------------------------------------ --------------- --------------- ---------------
  **Sex**                                                                    

  Male                                       4               5               

  Female                                     1               1               

  **Age**                                                                    

  Range (years)                              39--67          24--75          

  Mean                                       51.4            54.7            0.75

  **Overall survival**                                                       

  Range (days)                               393--1451       192--2462       

  Mean                                       1002.8          827.2           0.69

  **Primary tumor site**                                                     

  Unknown primary                            2               0               

  Back                                       1               1               

  Leg                                        2               3               

  Head/Neck                                  0               2               

  Mean S100 prior to targeted therapy μg/l   0.41            1.06            0.30

  Mean LDH prior to targeted therapy U/l     244.8           328.5           0.33
  ------------------------------------------------------------------------------------------

###### 

Switching from targeted to immunotherapy when a partial or complete response is achieved.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Sex**   **Age**   **Primary tumor**   **Rx 1**           **S100 Normal value \<0.11 μg/l**   **LDH Normal value \<250 U/l**   **Pre-Switch response**   **Duration (days)**   **Rx 2**                         **S100 2**   **LDH 2**   **Duration 2**   **Rx 3**               **S100 3**   **LDH 3**   **Duration 3**   **Rx 4**                **S100 4**   **LDH 4**   **Duration 4**   **Rx 5**                       **S100 5**   **LDH 5**   **Duration 5**   **Rx 6**             **S100 6**   **LDH 6**   **Duration 6**   **Rx 7**                                **S100 7**   **LDH 7**   **Duration 7**   **OS (days)/Status**
  --------- --------- ------------------- ------------------ ----------------------------------- -------------------------------- ------------------------- --------------------- -------------------------------- ------------ ----------- ---------------- ---------------------- ------------ ----------- ---------------- ----------------------- ------------ ----------- ---------------- ------------------------------ ------------ ----------- ---------------- -------------------- ------------ ----------- ---------------- --------------------------------------- ------------ ----------- ---------------- ----------------------
  M         50        MUP                 Vem/Cobi           0.09                                207                              PR                        152                   Nivolumab/Ipilimumab             0.08         302         433              Vem/Cobi               0.99         273         356              Nivolumab 3 mg/kg x 1   0.11         310         215              Enco/Bini                      0.30         233         271                                                                                                                                                               1299 - Alive

                                                                                                                                                                                  4 Cycles                                                                   Thrombocytopenia                                                 Nivolumab 480 mg                                                                                                                                                                                                                                                                            

                                                                                                                                                                                  Autoimmune hepatits grade 3                                                Prednisolone 1 mg/kg                                             7 Cycles                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                  Prednisolone 2 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                  Cellcept 1 g b.d.                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                  Nivolumab 3 mg/kg monotherapy                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                  3 Cycles                                                                                                                                                                                                                                                                                                                                                                                                                                

  F         43        Nodular Melanoma    Dab/Tram           0.18                                179                              CR                        210                   Nivolumab/Ipilimumab             0.05         215         43               Dab/Tram               0.07         189         80               Nivolumab 3 mg/kg       0.05         183         107              Vem/Cobi                       0.08         178         10               Ipilimumab 3 mg/kg   0.08         172         54               Dab/Tram                                0.44         174         655              1280 - Alive

                      Left thigh                                                                                                                                                  1 Cycle                                                                                                                                     8 Cycles                                                          Sepsis                                                                   Nivolumab 1 mg/kg                                              Sarcoidosis                                                                       

                                                                                                                                                                                  Autoimmune thyroiditis grade 3                                                                                                              Radiotherapy                                                      Drug-induced exanthem                                                    4 Cycles                                                       Cellultis                                                                         

                                                                                                                                                                                  Mumps infection                                                                                                                                                                                                                                                                                                                                       Exzision of a subcutaneous metastasis                                             

                                                                                                                                                                                  Exzision of a subcutaneous                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                  metastasis                                                                                                                                                                                                                                                                                                                                                                                                                              

  M         67        Melanoma            Vem (2 × 960 mg)   1.43                                407                              PR                        54                    Ipilimumab 3 mg/kg               0.05         181         78               Dab/Tram               1.66         343         196              Nivolumab 3 mg/kg       0.41         308         30                                                                                                                                                                                                                                         393 - Dead

                      Left thigh                                                                                                                                                  4 Cycles                                                                                                                                    2 Cycles                                                                                                                                                                                                                                                                                    

  M         39        SSM                 Vem/Cobi           0.29                                262                              PR                        303                   Nivolumab/Ipilimumab             0.05         327         54               Vem/Cobi               0.04         204         161              Pembrolizumab 2 mg/kg   0.05         312         168              Ipilimumab/Nivolumab           0.04         191         544              Enco/Bini            0.05         218         13                                                                                                 1451 - Alive

                      Back                                                                                                                                                        4 Cycles                                                                                                                                    8 Cycles                                                          2 Cycles\                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                Pembrolizumab                                                                                                                                                                                                             

                                                                                                                                                                                  Autoimmune thyroiditis grade 3                                                                                                              Radiotherapy                                                      8 Cycles 2 mg/kg                                                                                                                                                                                                          

                                                                                                                                                                                  Autoimmune hepatitis grade 2                                                                                                                                                                                  Pembrolizumab 200 mg                                                                                                                                                                                                      

                                                                                                                                                                                  Prednisolone 1 mg/kg                                                                                                                                                                                          11 Cycles fortnightly                                                                                                                                                                                                     

                                                                                                                                                                                  Neutropenia                                                                                                                                                                                                   Pembrolizumab 400 mg                                                                                                                                                                                                      

                                                                                                                                                                                  Nivolumab 3 mg/kg monotherapy                                                                                                                                                                                 2 Cycles in 3 week intervals                                                                                                                                                                                              

                                                                                                                                                                                  6 Cycles                                                                                                                                                                                                      Radiotherapy                                                                                                                                                                                                              

  M         58        MUP                 Vem/Cobi           0.06                                169                              CR                        188                   Nivolumab/Ipilimumab             0.09         207         96               Enco/Bini              0.07         193         293                                                                                                                                                                                                                                                                                                          591 - Alive

                                                                                                                                                                                  4 Cycles                                                                   Radiotherapy                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                  Colitis grade 3                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                  Prednisolone 1 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*The clinical course in patients electively switched from targeted to immune therapy based on the clinical response*.

*Dabra/Tram, Dabrafenib/Trametinib; Enco/Bini, Encorafenib; Binimetinib; LDH, lactate dehydrogenase; MUP, melanoma of unknown primary; SSM, superficial spreading melanoma; CR, complete response; PD, progressive disease; PR, partial response; Vem/Cobi; Vemurafenib/Cobimetinib*.

###### 

Switching from targeted to immunotherapy due to disease progression or intolerable side-effects.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Sex**                              **Age**   **Primary tumor**   **Rx 1**       **S100 1**   **LDH 1**   **Pre-Switch response**                **Duration**   **Rx 2**                  **S100 2**   **LDH 2**   **Duration 2**   **Rx 3**           **S100 3**   **LDH 3**   **Duration**\   **Rx 4**                   **S100 4**   **LDH 4**   **Duration 4**   **Rx 5**   **S100 5**   **LDH 5**   **Duration 5**   **Rx 6**             **S100 6**   **LDH 6**   **Duration 6**   **Rx 7**    **Rx 8**   **Rx 9**    **Rx 10**   **Rx 11**              **OS (days)/Status**
                                                                                                                                                                                                                                                                                   **3**                                                                                                                                                                                                                                                                          
  ------------------------------------ --------- ------------------- -------------- ------------ ----------- -------------------------------------- -------------- ------------------------- ------------ ----------- ---------------- ------------------ ------------ ----------- --------------- -------------------------- ------------ ----------- ---------------- ---------- ------------ ----------- ---------------- -------------------- ------------ ----------- ---------------- ----------- ---------- ----------- ----------- ---------------------- ----------------------
  M                                    75        SSM                 Dab/Tram       0.37         267         Therapy changed due to side effects:   85             Vem/Cobi                  0.17         371         219              Nivolumab          0.06         203         91              Nivolumab/\                0.11         223         115                                                                                                                                                                                                        547 - Dead
                                                                                                                                                                                                                                                                                                   Ipilimumab                                                                                                                                                                                                                                                     

                                                 Right Thigh                                                                                                                                                                           3 mg/kg 7 Cycles                                            2 Cycles                                                                                                                                                                                                                                                       

                                                                                                             Recurrent Pyrexia                                                                                                                                                                     Radiotherapy                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                   Colitis Grade 3                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                   Prednisolone 1 mg/kg                                                                                                                                                                                                                                           

  F                                    45        Nodular Melanoma    Dab then Vem   1.17         258         Therapy changed due to side effects:   101            Dacarbazine               0.156        187         71               Ipilimumab         3.03         383         79              Nivolumab\                 4.11         366         196              Vem        8.49         634         707              Ipilimumab 3 mg/kg   197          0.06        92               Nivolumab   Vem/\      Nivolumab   Vem/\       Ipilimumab/Nivolumab   2462 - Alive
                                                                                                                                                                                                                                                                                                   3 mg/kg                                                                                                                                                                                              Cobi                   Cobi                               

                                                 Back                                                                                                              250 mg/m^2^ over 5 days                                             3 mg / kg                                                   14 Cycles                                                            Vem/Cobi                                             2 Cycles                                                                              480 mg                  3 mg/kg and 1 mg/kg    

                                                                                                             Retinitis Serosa                                      3 Cycles                                                            4 Cycles                                                    Radiotherapy                                                                                                              Radiotherapy                                                                          2 Cycles                4 Cycles               

  M                                    24        SSM                 Enco/Bini      3.13         575         PD                                     224            Nivolumab/\               0.64         420         23               Dab/Tram           2.51         755         32              Dacarbazine 1000 mg/m^2^   3.98         620                                                                                                                                                                                                                    368 - Dead
                                                                                                                                                                   Ipilimumab                                                                                                                                                                                                                                                                                                                                                                                     

                                                 Back                                                                                                              2 Cycles                                                            Radiotherapy                                                2 Cycles                                                                                                                                                                                                                                                       

                                                                                                                                                                   Radiotherapy                                                                                                                                                                                                                                                                                                                                                                                   

  M                                    54        Nodular Melanoma    Dab/Tram       0.12         214         PD                                     62             Nivolumab 3 mg/kg         0.16         308                                                                                                                                                                                                                                                                                                                                                     192 - Dead

                                                 Back                                                                                                              5 Cycles                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                   Radiotherapy                                                                                                                                                                                                                                                                                                                                                                                   

  M                                    56        Nodular Melanoma    Dab/Tram       N/A          467         PD                                     318            Nivolumab/\               0.03         195                                                                                                                                                                                                                                                                                                                                                     329 - Dead
                                                                                                                                                                   Ipilimumab                                                                                                                                                                                                                                                                                                                                                                                     

                                                 Neck                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  M[^\*^](#TN1){ref-type="table-fn"}   74        Nodular Melanoma    Enco/Bini      0.53         190         PD                                     284            Pembrolizumab             0.03         179         203              Cobi/Vem           173          0.04        69              Pembrolizumab              0.04         168         456                                                                                                                                                                                                        1065 - Dead

                                                 Right ear                                                                                                         10 Cycles                                                           Surgery                                                     20 Cycles                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                       Radiotherapy                                                                                                                                                                                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*The clinical course is detailed in patients switched from targeted to immune therapy due to disease progression or intolerable treatment related side-effects*.

*The patient committed suicide during the study period*.

*Dabra/Tram, Dabrafenib/Trametinib; Enco/Bini, Encorafenib; Binimetinib; LDH, lactate dehydrogenase; MUP, melanoma of unknown primary; SSM, superficial spreading melanoma; CR, complete response; PD, progressive disease; PR, partial response; Vem/Cobi; Vemurafenib/Cobimetinib*.

As expected with two small cohorts, there was no significant difference in terms of the length of overall survival between the groups. However, it is worth noting that the clinical course in Patient 2 (reactive group) differed markedly from that of the other patients in the cohort. Not only did the patient initially receive monotherapy with BRAF inhibition, but the patient also received chemotherapy with dacarbazine prior to being switched to ipilimumab. The patient was only then switch to combined targeted therapy due to disease progression.

Interestingly, exclusion of the outlier patient and the patient who committed suicide in the reactive group revealed a significant (*p* = 0.01) difference in overall survival.

Moreover, the average length of overall survival in the elective group was 1,003 days compared to 827 days in the reactive group. At last follow up, 83% of the patients in the reactive cohort had died, including one patient who committed suicide whilst only one patient (20%) in the elective group had died.

Discussion {#s4}
==========

An overall survival benefit of elective switching from targeted to immunotherapy could be demonstrated in 4 out of 5 cases, with a maximal OS of up to almost 4 years. In each of these patients the decision to switch from targeted therapy to immunotherapy was made electively at the time of complete or partial response, given the overall clinical response and to prevent the development of treatment resistance.

Initial treatment with targeted therapy may be favored in patients with a BRAF V600 mutation in the context of a large tumor burden and adverse prognostic factors (including increased LDH) in whom rapid disease control is of paramount importance. Whether initial treatment with checkpoint immunotherapy in patients with BRAF mutations, provides any long-term and durable therapeutic advantages over targeted therapy remains the subject of intense investigation. As outlined by Luke et al. the decision to initiate targeted therapy may be favored when rapid disease control and/or immune-priming effects are required, whereas increased LDH and avoidance of resistance may favor initial checkpoint therapy ([@B13]).

Ackerman et al. analyzed the outcome of 274 patients treated with immunotherapy prior to (*n* = 32) or after (*n* = 242) BRAF inhibition. This retrospective study reported that prior treatment with targeted therapy did not negatively influence the response to subsequent immunotherapy with ipilimumab. However, outcomes for patients treated with ipilimumab following BRAF inhibition were poor ([@B14]). It should be noted that this was retrospective study and at the time the only licensed immunotherapy was monotherapy with ipilimumab. Aya et al. ([@B8]) failed to uncover any differences in overall survival in a small retrospective cohort study specifically comparing targeted then immune therapy and vice versa. However, results from prospective trials examining sequential therapy, e.g., NCT02224781 or SECOMBIT (NCT02631447) with additional checkpoint inhibitors, are eagerly anticipated.

The combination of targeted therapy and immunotherapy, either in a parallel or sequential manner, could theoretically lead to enhanced anti-tumor responses, reflected in durable responses and prolonged survival. In fact, the length of response to BRAF/MEK inhibition may be key. For example, Ascierto et al. reported that in patients who responded to BRAF/MEK inhibition for over 6 months, the overall response rate to subsequent anti-PD1 therapy was 34% ([@B15]). In contrast, when patients benefits for \<6 months, the overall response rate to subsequent anti-PD1 therapy was only 15%. This sits well with the evidence that BRAF inhibition can improve the efficacy of PD-1 blockade via changes in the tumor microenvironment ([@B10], [@B15], [@B16]). In fact, BRAF/MAPK targeted therapy can alter the immune environment within 2 weeks ([@B16]), resulting in elevated PD-L1 expression for up to 3 months ([@B17]). It is however important to bear in mind that these changes may be temporary, perhaps opening up a therapeutic window in which the potential benefits from switching to immune therapy can be harnessed. Other authors have reported complete and durable remission using finite courses of BRAF inhibition following failure to respond to immunotherapy ([@B18]). However, these observations are based on small case series. Most recently concern has been raised about the tolerability and side effect profile of BRAF/MEK inhibition after anti-PD-1 therapy ([@B19]). Indeed, the authors speculated that the increased incidence of treatment interruptions may impact upon the rates of OS.

In contrast to this observation ([@B19]), it has been reported that initial anti-PD-1 therapy in patients with BRAF mutations may be associated with improved overall survival when compared to patients initially treated with targeted therapy ([@B20]). Despite being a multi-centric analysis, these data were again retrospective.

Overall, we witnessed fewer treatment related toxicities in the reactive switch group. Given that the development of toxicities is associated with an improved response to immunotherapy ([@B21]), the lack of side-effects correlated well with the lack of disease control and overall poorer prognosis.

A major limitation of our case series is its retrospective nature. Decisions on which targeted therapies and which immune checkpoint therapies were administered (anti-PD-1 monotherapy vs. combined anti-PD-1 and anti-CTLA-4 therapy) were taken by the multi-disciplinary tumor board. These decisions were based on tumor factors (tumor activity and overall disease burden) and patient factors (including relevant co-morbidities). Whilst the various treatment combinations and retrospective nature of the analysis could be interpreted as weaknesses, it should nevertheless be borne in mind that the data reflect the "real-life" clinical management of metastatic melanoma.

Summarizing the results of sequential therapy in our cohort, it is reasonable to conclude that switching between targeted and immune checkpoint therapy, and vice versa, which can be complemented by radiotherapy of brain metastases, may be associated with improved long-term survival, even in patients with an extensive disease burden. This treatment strategy may be useful strategy to prevent the development of resistance to MEK/BRAF inhibition. However, given the historical context of our retrospective analysis which meant that all patients were initially treated with targeted therapy, no conclusions can be drawn on which upfront treatment strategy is best.

In the absence of evidence-based clinical data, the decision to switch between targeted and immune checkpoint based therapy and the importance of timing in terms of switching treatment modality remains a clinical conundrum ([@B22]). Indeed, with increasing rates and duration of overall survival, the specific contribution of the upfront therapy and therapy switches to any survival benefit is difficult to ascertain. Moreover, progression-free survival is also of limited benefit to measure treatment efficacy, given that targeted therapy treatment may be switched to immune therapy "electively" before tumor progression to prevent the development of resistance. Identifying the optimal time to switch therapy, depending on the duration and extent of the response to treatment, remains to be determined definitively. However, the publication of non-selected real-life clinical data reporting the long-term efficacy and tolerability of sequential therapy may help inform clinical practice until the definitive results from the on-going, prospective, and multi-center clinical trials are available.
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